Why Walmart’s quick success in generative AI search should have Google worried

Walmart is talking up its ability to layer generative AI into search within its website for more customized shopping. Should Google be worried?
Why Walmart’s quick success in generative AI search should have Google worried

Walmart is talking up its ability to layer generative AI into search within its website for more customized shopping. Should Google be worried?
Why Walmart’s quick success in generative AI search should have Google worried

Walmart is talking up its ability to layer generative AI into search within its website for more customized shopping. Should Google be worried?
Why Walmart’s quick success in generative AI search should have Google worried

Walmart is talking up its ability to layer generative AI into search within its website for more customized shopping. Should Google be worried?
Why Walmart’s quick success in generative AI search should have Google worried

Walmart is talking up its ability to layer generative AI into search within its website for more customized shopping. Should Google be worried?
Pfizer is betting big on cancer drugs to turn business around after Covid decline – here’s what to know

The pharmaceutical giant has been trying to shore up investor sentiment after its shares fell more than 40% in 2023.
Pfizer is betting big on cancer drugs to turn business around after Covid decline – here’s what to know

The pharmaceutical giant has been trying to shore up investor sentiment after its shares fell more than 40% in 2023.
Pfizer is betting big on cancer drugs to turn business around after Covid decline – here’s what to know

The pharmaceutical giant has been trying to shore up investor sentiment after its shares fell more than 40% in 2023.
Pfizer is betting big on cancer drugs to turn business around after Covid decline – here’s what to know

The pharmaceutical giant has been trying to shore up investor sentiment after its shares fell more than 40% in 2023.
Pfizer is betting big on cancer drugs to turn business around after Covid decline – here’s what to know

The pharmaceutical giant has been trying to shore up investor sentiment after its shares fell more than 40% in 2023.